The weekly brief · free to read, free to cite
National Coding and Telehealth Updates Take Center Stage in a Federal-Only Week
Week of August 31 – September 6, 2026
All five items this week trace back to national policy, with no single MAC jurisdiction bearing sole responsibility for implementation. The mix spans SNF billing enforcement, hospice recertification documentation, new drug approvals, and Medicaid program integrity chapters — a reminder that federal-level changes can reach every contractor's book of business at once, even in a week without a headline rule.
CLV Intelligence™ reviewed 33 publications across all 16 Medicare Administrative Contractor jurisdictions this week. 5 are covered below. Every item links its primary government source.
Lead item
CMS Transmittal R13943CP: October 2026 Quarterly Update to Healthcare Common Procedure Coding System (HCPCS) Codes Used…
- Jurisdiction
- National
- Specialty
- Multi-specialty
- Type
- coding_change
- Effective
- October 5, 2026
This transmittal governs how SNF consolidated billing enforcement recognizes HCPCS codes, a mechanism that determines whether services get bundled into or excluded from the facility's payment. Coding and billing staff working under consolidated billing arrangements sit closest to any misalignment.
Item 2
CMS Transmittal R13944CP: Reporting Face-to-Face Encounter Conducted by a Hospice Physician or Hospice Nurse Practitioner…
- Jurisdiction
- National
- Specialty
- Hospice
- Type
- transmittal
- Effective
- January 4, 2027
The change touches how hospice recertification face-to-face encounters get documented when conducted by phone or video rather than in person, a documentation pathway that hospice compliance and physician-liaison teams will need to track closely given the runway before it takes hold.
Item 3
FDA Approval: MIMRYLO (RUSFERTIDE ACETATE) — Type 1 - New Molecular Entity
- Jurisdiction
- National
- Specialty
- Hematology
- Type
- federal_register
- Effective
- August 28, 2026
A newly approved molecular entity in hematology introduces a product with no established billing history, leaving payer coverage and coding treatment as open questions for practices that begin administering it.
Item 4
FDA Approval: VOBRIG (LEUPROLIDE ACETATE) — Type 5 - New Formulation or New Manufacturer
- Jurisdiction
- National
- Specialty
- Oncology
- Type
- billing_update
- Effective
- August 26, 2026
This is a new formulation or manufacturer approval rather than a novel drug, but oncology practices dispensing or administering it will still face the task of mapping the new NDC or formulation to existing billing pathways.
Item 5
CMS Transmittal R13945MPI: Updates to Chapter 3, Chapter 4, and Chapter 5 in Publication (Pub.) 100-15, Including Updates…
- Jurisdiction
- National
- Specialty
- Medicaid
- Type
- transmittal
- Effective
- October 5, 2026
Updates spanning multiple chapters of the Medicaid integrity manual touch the vetting process and how overpayment records get created, mechanisms that sit at the center of state and MCO program integrity operations and the providers who get flagged through them.
A federally driven week rather than a contractor-driven one, with three items still carrying effective dates ahead. Billing, hospice, and Medicaid integrity teams each have a distinct thread to watch as the runway plays out.
See what changed in your jurisdiction
This brief covers the week. The free 90-day snapshot covers your specialty and your MAC — every policy change on record, with its source.
CLV Intelligence monitors and summarizes publicly available federal and MAC publications. It is not legal, medical, billing, or coding advice.